Pain Therapeutics, Inc. (NASDAQ:PTIE) – Investment analysts at Gabelli issued their FY2021 earnings estimates for shares of Pain Therapeutics in a research report issued to clients and investors on Thursday. Gabelli analyst K. Kedra expects that the brokerage will post earnings of ($0.35) per share for the year.
Separately, Zacks Investment Research lowered Pain Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 30th.
Shares of Pain Therapeutics (NASDAQ:PTIE) opened at 0.86 on Friday. The company has a 50-day moving average of $0.65 and a 200 day moving average of $0.85. The firm’s market cap is $39.68 million. Pain Therapeutics has a 52-week low of $0.51 and a 52-week high of $3.00.
Institutional investors have recently bought and sold shares of the company. Gabelli Funds LLC raised its position in Pain Therapeutics by 9.4% in the fourth quarter. Gabelli Funds LLC now owns 175,000 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 15,000 shares during the last quarter. Acadian Asset Management LLC raised its stake in shares of Pain Therapeutics by 26.3% in the third quarter. Acadian Asset Management LLC now owns 443,430 shares of the biopharmaceutical company’s stock worth $444,000 after buying an additional 92,358 shares in the last quarter. Spark Investment Management LLC acquired a new stake in shares of Pain Therapeutics during the third quarter worth $119,000. Finally, BVF Inc. IL raised its stake in shares of Pain Therapeutics by 6.0% in the third quarter. BVF Inc. IL now owns 2,278,552 shares of the biopharmaceutical company’s stock worth $2,278,000 after buying an additional 128,639 shares in the last quarter. Institutional investors and hedge funds own 44.34% of the company’s stock.
Pain Therapeutics Company Profile
Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.
Receive News & Ratings for Pain Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pain Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.